Biomarkers to Reveal Response Rate in Patients when Given Immune Checkpoint Inhibitor Drugs
Release Date: 22-Nov-2020
It is recorded for majority of the patients that immune checkpoint inhibitors are not as effective as observed for some of the patients. To end this, a group of researchers have identified some clinical markers that may help the researchers to evaluate the response rate the patient is going to achieve for immune checkpoint inhibitors. For the same, the researchers implanted breast cancer cells in the mice model and further treated the mice model with immune checkpoint inhibitors. It was observed by the researchers that the mice models that recorded response were having high number of CTL cells and a smaller number of immune suppressor cells.
Researchers recorded that distinct gene signatures were able to distinguish the patients who are or are not going to response to the treatment. It was found by the researchers that gene signatures for responder and non-responder tumors was related with responder and non-responder gene signatures derived from patients with melanoma who were treated with immune checkpoint inhibitors and overall survival in a group of patients suffering from breast cancer. Now the primary aim of the researchers is to identity and develop a strong combination therapy that could really boost the treatment efficacy of the immune checkpoint inhibitor drugs so that patients suffering from cancer could receive benefit.
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.